167 related articles for article (PubMed ID: 38256056)
1. BMP9-ID1 Pathway Attenuates N
Chen H; Zhang M; Li J; Liu M; Cao D; Li YY; Yamashita T; Nio K; Tang H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256056
[TBL] [Abstract][Full Text] [Related]
2. BMP9-ID1 Signaling Activates HIF-1α and VEGFA Expression to Promote Tumor Angiogenesis in Hepatocellular Carcinoma.
Chen H; Nio K; Tang H; Yamashita T; Okada H; Li Y; Doan PTB; Li R; Lv J; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163396
[TBL] [Abstract][Full Text] [Related]
3. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.
Chen H; Nio K; Yamashita T; Okada H; Li R; Suda T; Li Y; Doan PTB; Seki A; Nakagawa H; Toyama T; Terashima T; Iida N; Shimakami T; Takatori H; Kawaguchi K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Mol Oncol; 2021 Aug; 15(8):2203-2218. PubMed ID: 33834612
[TBL] [Abstract][Full Text] [Related]
4. BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.
Herrera B; García-Álvaro M; Cruz S; Walsh P; Fernández M; Roncero C; Fabregat I; Sánchez A; Inman GJ
PLoS One; 2013; 8(7):e69535. PubMed ID: 23936038
[TBL] [Abstract][Full Text] [Related]
5. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
6. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
[TBL] [Abstract][Full Text] [Related]
7. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.
Wang F; Hu Y; Wang H; Hu P; Xiong H; Zeng Z; Han S; Wang D; Wang J; Zhao Y; Huang Y; Zhuo W; Lv G; Zhao G
J Exp Clin Cancer Res; 2023 Oct; 42(1):267. PubMed ID: 37840133
[TBL] [Abstract][Full Text] [Related]
8. AMD1 upregulates hepatocellular carcinoma cells stemness by FTO mediated mRNA demethylation.
Bian X; Shi D; Xing K; Zhou H; Lu L; Yu D; Wu W
Clin Transl Med; 2021 Mar; 11(3):e352. PubMed ID: 33783988
[TBL] [Abstract][Full Text] [Related]
9. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
10. BMP9 attenuates occurrence of venous malformation by maintaining endothelial quiescence and strengthening vessel walls via SMAD1/5/ID1/α-SMA pathway.
Li Y; Shang Q; Li P; Yang Z; Yang J; Shi J; Ge S; Wang Y; Fan X; Jia R
J Mol Cell Cardiol; 2020 Oct; 147():92-107. PubMed ID: 32730768
[TBL] [Abstract][Full Text] [Related]
11. Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue.
Nakagawa N; Tanaka K; Sonohara F; Kandimalla R; Sunagawa Y; Inokawa Y; Takami H; Hayashi M; Yamada S; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
Anticancer Res; 2020 Dec; 40(12):6665-6676. PubMed ID: 33288560
[TBL] [Abstract][Full Text] [Related]
12. LNCAROD enhances hepatocellular carcinoma malignancy by activating glycolysis through induction of pyruvate kinase isoform PKM2.
Jia G; Wang Y; Lin C; Lai S; Dai H; Wang Z; Dai L; Su H; Song Y; Zhang N; Feng Y; Tang B
J Exp Clin Cancer Res; 2021 Sep; 40(1):299. PubMed ID: 34551796
[TBL] [Abstract][Full Text] [Related]
13. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
Hao W; Chen Z; Tang J; Yang R; Gao WQ; Xu H
J Transl Med; 2023 Nov; 21(1):861. PubMed ID: 38017546
[TBL] [Abstract][Full Text] [Related]
14. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of sorafenib against hepatocellular carcinoma is enhanced by 5-aza-mediated inhibition of ID1 promoter methylation.
Meng J; Li S; Niu ZQ; Bao ZQ; Niu LL
FEBS Open Bio; 2024 Jan; 14(1):127-137. PubMed ID: 37964494
[TBL] [Abstract][Full Text] [Related]
16. GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation.
Ding H; Zhang X; Su Y; Jia C; Dai C
Cell Mol Biol Lett; 2020; 25():8. PubMed ID: 32123532
[TBL] [Abstract][Full Text] [Related]
17. CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma.
Liu L; Gu M; Ma J; Wang Y; Li M; Wang H; Yin X; Li X
Mol Cancer; 2022 Jul; 21(1):149. PubMed ID: 35858900
[TBL] [Abstract][Full Text] [Related]
18. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.
Jung JW; Yoon SM; Kim S; Jeon YH; Yoon BH; Yang SG; Kim MK; Choe S; Kuo MM
Oncotarget; 2016 Nov; 7(45):73754-73768. PubMed ID: 27650540
[TBL] [Abstract][Full Text] [Related]
19. Role of bone morphogenetic protein-9 in the regulation of glucose and lipid metabolism.
Yang M; Liang Z; Yang M; Jia Y; Yang G; He Y; Li X; Gu HF; Zheng H; Zhu Z; Li L
FASEB J; 2019 Sep; 33(9):10077-10088. PubMed ID: 31237775
[TBL] [Abstract][Full Text] [Related]
20. [LncRNA HULC promots HCC growth by downregulating miR-29].
Zhu LR; Feng JL; Liu XJ; Wang JM
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):659-666. PubMed ID: 31550855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
